Mankind Pharma Peer Comparison

Snapshot Summary

Mankind Pharma Ltd. showcases strong profitability and growth relative to its peers, while maintaining low debt levels, making it an attractive pick in the Pharmaceuticals & Drugs industry. However, it has a relatively high valuation compared to its growth prospects, suggesting a balanced outlook with potential caution for new investors.

• Mankind Pharma has the highest revenue growth YoY (18.12%) and strong EPS growth (48.24%).
• Dr. Reddy's Laboratories ranks highest in profitability metrics like ROE (21.76%) and EBITDA margin (27.09%).
• Mankind has a low debt-equity ratio (0.021), indicating strong financial stability.

• Mankind Pharma Ltd.: Highest revenue growth YoY (18.12%) and strong EPS growth (48.24%).
• Dr. Reddy's Laboratories Ltd.: Highest ROE (21.76%) and significant profitability with low valuation metrics.
• Cipla Ltd.: Best valuation attractiveness with a low PE (23.73) and high profitability.

Stock	CMP	Market Cap	P/E	ROE (%)	ROCE (%)	Debt/Equity
MANKIND	₹2,399.50	₹99,138.40Cr	52.38	16.98%	18.32%	0.58
SUNPHARMA	₹1,706.40	₹4,09,626.46Cr	39.49	16.16%	19.89%	0.03
DIVISLAB	₹6,804.00	₹1,80,668.62Cr	78.35	15.35%	20.45%	0.00
TORNTPHARM	₹3,628.30	₹1,20,456.12Cr	60.17	26.46%	27.32%	0.40
CIPLA	₹1,511.50	₹1,22,102.70Cr	22.44	16.63%	22.77%	0.01
DRREDDY	₹1,196.00	₹99,965.86Cr	17.32	18.61%	23.25%	0.14
ZYDUSLIFE	₹981.05	₹98,057.50Cr	21.45	21.08%	26.06%	0.13

Explore

Watchlists

Command Palette

Mankind Pharma Peer Comparison

Snapshot Summary